Centre National De La Recherche Scientifique

Idenix Pharmaceuticals, Inc.

Universitá Degli Studi Di Cagliari

L'université Montpellier Ii

University of Cagliari

L'universite Montfellier Ii

Universitè De Montpellier

Idenix Limited

Gilles Gosselin

Adel M Moussa

Jean-Louis Imbach

Martin L Bryant

Cyril B Dousson

David Dukhan

Dominique Surleraux

Francois-Rene Alexandre

Benjamin Alexander Mayes

Jean-Laurent Paparin

Claire Pierra

Alistair James Stewart

Christian Perigaud

Houcine Rahali

Paola LaColla

Jean-Pierre Sommadossi

Suzanne Peyrottes

Richard Storer

Guillaume Brandt

Paolo La Colla

Rachid Rahali

Jean-François Griffon

François-René Alexandre

Christophe Claude Parsy

2' and/or 3&#x2032; prodrugs of 1&#x2032;, 2&#x2032;, 3&#x2032; or 4&#x2032;-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

Modified 2' and 3&#x2032;-nucleoside prodrugs for treatinginfections

2' and 3&#x2032;-Prodrugs of 1&#x2032;, 2&#x2032;, 3&#x2032; or 4&#x2032;-branched &#x3b2;-D or &#x3b2;-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA dependent RNA reverse transcriptase. Compounds, compositions, methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

2' and 3&#x2032;-nucleoside prodrugs for treatinginfections

2' and/or 3&#x2032; prodrugs of 1&#x2032;, 2&#x2032;, 3&#x2032; or 4&#x2032;-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

Modified 2' and 3&#x2032;-nucleoside prodrugs for treating Flaviviridae infections

Growing community of inventors

Monpellier, France

Gilles Gosselin